Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 3,638 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jereme Sylvain sold 3,638 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the transaction, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Up 2.0%

Shares of NASDAQ:DXCM traded up $1.65 during trading hours on Monday, hitting $84.68. The company’s stock had a trading volume of 2,493,694 shares, compared to its average volume of 5,119,560. The firm’s fifty day moving average price is $82.75 and its 200 day moving average price is $72.80. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The company has a market capitalization of $31.95 billion, a price-to-earnings ratio of 33.47, a P/E/G ratio of 1.39 and a beta of 1.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period last year, the firm earned $0.48 earnings per share. As a group, research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent research reports. Argus increased their target price on DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Raymond James Financial restated a “strong-buy” rating and set a $94.00 price objective on shares of DexCom in a research note on Friday, July 31st. Royal Bank Of Canada raised their price objective on DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Truist Financial set a $93.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Stifel Nicolaus set a $95.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $88.71.

Hedge Funds Weigh In On DexCom

A number of large investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its holdings in shares of DexCom by 6,567.7% during the 2nd quarter. California State Teachers Retirement System now owns 39,176,552 shares of the medical device company’s stock valued at $2,638,541,000 after purchasing an additional 38,588,991 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after buying an additional 1,515,702 shares in the last quarter. Geode Capital Management LLC increased its position in DexCom by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after buying an additional 42,411 shares in the last quarter. Norges Bank purchased a new stake in DexCom in the fourth quarter valued at about $483,356,000. Finally, Legal & General Group Plc purchased a new stake in DexCom in the second quarter valued at about $173,237,000. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.